dm+d

Unassigned

New Medicines

Non-alcoholic steatohepatitis (NASH) with stage 2 or 3 liver fibrosis in people who are overweight or obese and have pre-diabetes or type 2 diabetes

Information

New molecular entity
Galmed Pharmaceuticals
Galmed Pharmaceuticals

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

A fatty acid bile acid conjugate (FABAC), taken once daily
NASH is a serious liver disease resulting from metabolic dysfunction that is associated with steatosis (fat within the liver), inflammation and fibrosis, which may progress to cirrhosis. NASH-related cirrhosis is expected to become the leading indication for liver transplantation by 2020 [1].
Non-alcoholic steatohepatitis (NASH) with stage 2 or 3 liver fibrosis in people who are overweight or obese and have pre-diabetes or type 2 diabetes
Oral